Esperion has one ongoing Phase 3 trial for bempedoic acid: In 2016, we initiated a global cardiovascular outcomes trial (CVOT) – CLEAR Outcomes – with nearly 14,000 patients in 32 countries. CLEAR Outcomes is the first CVOT that specifically enrolled patients with statin intolerance, and is an event-driven, randomized, multicenter, double-blind, placebo-controlled trial designed to evaluate the effect of bempedoic acid on four-component major adverse cardiovascular events (MACE).
As part of Esperion’s commitment to transparency, summaries of clinical studies are available below. Please visit clinicaltrials.gov for more information on clinical trials.
For additional information on CLEAR Outcomes, please visit esperionscience.com.
Clinical Studies
Placeholder for no text
*Please Note: Esperion is subject to all applicable federal, state and/or local transparency laws and regulations related to the transfer of items of value such as educational items (e.g., journal articles) that may be provided to you in order to respond to your unsolicited request for medical information. Based on applicable laws and regulations, the value of any reportable transfer of value may be made publicly available.